NCT07158710View on ClinicalTrials.gov

Phase I Study of HSK42360 in Malignant Brain Tumors With BRAF V600 Mutation

PHASE1RecruitingINTERVENTIONAL
Enrollment

159

Participants

Timeline

Start Date

August 15, 2025

Primary Completion Date

May 23, 2029

Study Completion Date

December 3, 2029

Conditions
Malignant Brain Tumors
Interventions
DRUG

HSK42360

Oral administration, QD/BID

Trial Locations (6)

100021

RECRUITING

Xuanwu Hospital Capital Medical University, Beijing

100070

RECRUITING

Department of Neuro-oncology, Cancer Center, Beijing Tiantan Hospital, Capital Medical University,Beijing, China, Beijing

130000

RECRUITING

The Third Bethune Hospital of Jilin University, Changchun

200000

RECRUITING

Fudan University Affiliated Huashan Hospital, Shanghai

350200

RECRUITING

The first affiliated hospital of fujian medical university, Fuzhou

510280

RECRUITING

Zhujiang Hospital of Southern Medical University, Guangzhou

All Listed Sponsors
lead

Haisco Pharmaceutical Group Co., Ltd.

INDUSTRY